ReviewNeuropsychiatric disease and treatment2018
Neuropsychiatric disturbances in atypical parkinsonian disorders.
Review in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Prognostic factors of survival in corticobasal syndrome and corticobasal degeneration: A scoping review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration.Journal of neurology · 2026Article
- Suicide attempt by a patient with an early phase of progressive supranuclear palsy: a case report.BMC neurology · 2026Article
- Tryptophan Supplementation Reduces Schizophrenia-Like Symptoms in Apomorphine Treated Rats: Role of D2, GABA, and Glutamate Receptor Expression.International journal of tryptophan research : IJTR · 2026Article
- Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes.Brain : a journal of neurology · 2025Article
- A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy.Movement disorders clinical practice · 2025Article
- The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.European journal of neurology · 2025Article
- Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- The Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research.Diseases (Basel, Switzerland) · 2025Review
- The enigma of depression in corticobasal degeneration, a frequent but poorly understood co-morbidity.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study.Neuropsychiatric disease and treatment · 2024Article
- Neurological update: non-motor symptoms in atypical parkinsonian syndromes.Journal of neurology · 2023Article
- Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson's disease and atypical Parkinsonian syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022Review
- Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects.Frontiers in psychiatry · 2022Review
- Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy.Frontiers in neurology · 2021Article
- Atypical parkinsonian syndromes in a North African tertiary referral center.Brain and behavior · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) are the most common atypical parkinsonisms. These disorders are characterized by varying combinations of autonomic, cerebellar and pyramidal system, and cognitive dysfunctions. In this paper, we reviewed the evidence available on the presence and type of neuropsychiatric disturbances in MSA, PSP, and CBD. A MedLine, Excerpta Medica, PsycLit, PsycInfo, and Index Medicus search was performed to identify all articles published on this topic between 1965 and 2018. Neuropsychiatric disturbances including depression, anxiety, agitation, and behavioral abnormalities have been frequently described in these disorders, with depression as the most frequent disturbance. MSA patients show a higher frequency of depressive disorders when compared to healthy controls. An increased frequency of anxiety disorders has also been reported in some patients, and no studies have investigated apathy. PSP patients may have depression, apathy, disinhibition, and to a lesser extent, anxiety and agitation. In CBD, neuropsychiatric disorders are similar to those present in PSP. Hallucinations and delusions are rarely reported in these disorders. Neuropsychiatric symptoms in MSA, PSP, and CBD do not appear to be related to the severity of motor dysfunction and are one of the main factors that determine a low quality of life. The results suggest that neuropsychiatric disturbances should always be assessed in patients with atypical parkinsonisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.